Octreotide lar

Phase 3Peptide

Octreotide lar is one of 49 small molecule programs targeting Somatostatin Receptor Positive (SSTR+). It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Somatostatin Receptor Positive (SSTR+)Recruiting

Real-World StudyCompleted

Safety and EfficacyCompleted

Somatostatin Receptor Positive (SSTR+)Phase 3

Recruiting

Real-World StudyPreclinical

Completed

Safety and EfficacyPhase 3

Completed

Competition

Competitive Landscape

131 competitors in Safety and Efficacy

#DrugCompanyPhaseTrials

Avastin

Roche

Phase 3

3 2

Actemra

Roche

Phase 3

1 3

Humira

RRanbaxy Laboratories Limited

Phase 3

3 4

Rayos

RRoxane Laboratories

Phase 3

3 5

Empaveli

Apellis Pharmaceuticals

Phase 3

2 6

Gemzar

Johnson & Johnson

Phase 2

6 7

Fludara

Sanofi

Phase 2

5 8

CAB LA

GSK

Phase 3

1 9

Yervoy

Bristol-Myers Squibb

Phase 2

3 10

B/F/TAF

Gilead

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 3Recruiting

Safety and Efficacy

NCT07057622

Q4 2028

Phase 3Active, not recruiting

Gastroenteropancreatic Neuroendocrine Tumor

NCT05050942

Phase 3Active, not recruiting

Treatment

NCT05459844

Q1 2034

Phase 3Recruiting

Somatostatin Receptor Positive (SSTR+)

NCT06784752

Clinical

Trials by Indication[1]

Acromegaly6 trials

Acromegaly Combination Treatment Study

Terminated·—·N/A·NCT01538966·76 enrolled

Prediction of Tumor Shrinkage in Acromegaly

Completed·FFederico II University··NCT00616408·61 enrolled

Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With Acromegaly

Completed· Novartis logo

Novartis·Phase 3·NCT00225979·100 enrolled

Show 3 more trials

Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly

Completed· Novartis logo

Novartis·Phase 3·NCT01137682·198 enrolled

Ultrasound Guided Octreotide LAR Injection in Acromegaly

Completed·—·Phase 4·NCT00552071·15 enrolled

Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly

Completed·FFederico II University·Phase 4·NCT00461149·50 enrolled

Neuroendocrine Tumors2 trials

High Dose Somatostatin Analogues in Neuroendocrine Tumors

Completed·FFederico II University·Phase 2·NCT00990535·28 enrolled

Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut

Completed·CCarmen Schade-Brittinger·Phase 3·NCT00171873·85 enrolled

Treatment2 trials

A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours

Completed·AAdvanced Accelerator Applications·Phase 3·NCT01578239·231 enrolled

A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs

Active, not recruiting·SSinotau Pharmaceutical Group·Phase 3·NCT05459844·196 enrolled

Safety and Efficacy2 trials

Safety and Efficacy of Octreotide Long Acting Release (LAR) in Treatment Naïve Acromegalic Patients

Completed· Novartis logo

Novartis·Phase 3·NCT00128232·100 enrolled

A Phase III Clinical Study to Compare the Safety and Efficacy of 177Lu-DOTATATE Injection and Long-acting Oxytrexine in Adult Patients With NETs

Recruiting·HHTA Co., Ltd.·Phase 3·NCT07057622·184 enrolled

Peritoneal Carcinomatosis1 trial

Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis

Completed· Novartis logo

Novartis·Phase 2·NCT00332696·64 enrolled

13 more indications

Carcinoid Syndrome1 trial

P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome

Terminated·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT01886287·2 enrolled

Cystic1 trial

Everolimus and LongActing Octreotide Trial in Polycystic Livers

Completed·RRadboud University Medical Center·Phase 2·NCT01157858·44 enrolled

Adenoma1 trial

Surgical Debulking of Pituitary Adenomas

Completed·NNYU Langone Health·Phase 4·NCT01371643·41 enrolled

Real-world Study1 trial

Real-world Study on Adjuvant Octreotide Therapy in pNETs

Completed·—·N/A·NCT06080204·411 enrolled

Advanced1 trial

Phase II Study of Everolimus Combined With Octreotide LAR to Treat Advanced GI NET

Completed·GGrupo Espanol de Tumores Neuroendocrinos·Phase 2·NCT01567488·43 enrolled

Prostate Cancer1 trial

Effects of Octreotide Acetate on Circulating Levels of Chromogranin A in Advanced Prostate Cancer Patients

Completed· Novartis logo

Novartis·Phase 2·NCT00166725·40 enrolled

Bleeding1 trial

Octreotide in Patients With GI Bleeding Due to Rendu-Osler-Weber

Unknown status·RRadboud University Medical Center·Phase 2·NCT02874326·15 enrolled

ADPKD1 trial

Tolvaptan-Octreotide LAR Combination in ADPKD

Completed· Mario Negri Institute for Pharmacological Research logo

Mario Negri Institute for Pharmacological Research·Phase 2·NCT03541447·20 enrolled

Cirrhosis1 trial

Vasoconstrictors as Alternatives to Albumin After Large-Volume Paracentesis (LVP) in Cirrhosis

Completed·UUS Department of Veterans Affairs·Phase 4·NCT00108355·29 enrolled

Autosomal Dominant Polycystic Kidney Disease1 trial

Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Renal Insufficiency

Completed· Mario Negri Institute for Pharmacological Research logo

Mario Negri Institute for Pharmacological Research·Phase 3·NCT01377246·100 enrolled

Maintenance Treatment1 trial

Octreotide LAR as Maintenance Treatment for Patients With NEC

Unknown status·PPeking University·Phase 2·NCT02409849·92 enrolled

Somatostatin Receptor Positive (SSTR+)1 trial

A Phase III Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients Newly Diagnosed With Grade 1 and Grade 2 (Ki-67 <10%) Advanced GEP-NET With High Disease Burden (NETTER-3)

Recruiting· Novartis logo

Novartis·Phase 3·NCT06784752·240 enrolled

Gastroenteropancreatic Neuroendocrine Tumor1 trial

A Randomized, Multi-center, Open-label, Active-controlled Phase 3 Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) Versus Octreotide LAR or Lanreotide ATG in Patients With GEP-NET

Active, not recruiting·CCamurus AB·Phase 3·NCT05050942·332 enrolled

Sources

References

[1]
ClinicalTrials.gov — 26 trial records for Octreotide lar. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Octreotide lar compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Octreotide lar. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Peptide[2]
Highest Phase: Phase 3[1]
Company: Novartis

Octreotide lar

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2028

Q1 2034

Trials by Indication[1]

Acromegaly6 trials

Neuroendocrine Tumors2 trials

Treatment2 trials

Safety and Efficacy2 trials

Peritoneal Carcinomatosis1 trial

Carcinoid Syndrome1 trial

Cystic1 trial

Adenoma1 trial

Real-world Study1 trial

Advanced1 trial

Prostate Cancer1 trial

Bleeding1 trial

ADPKD1 trial

Cirrhosis1 trial

Autosomal Dominant Polycystic Kidney Disease1 trial

Maintenance Treatment1 trial

Somatostatin Receptor Positive (SSTR+)1 trial

Gastroenteropancreatic Neuroendocrine Tumor1 trial

References

Drug Info

Quick Facts

Related News